CELG - Celgene Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
89.27
-3.44 (-3.71%)
At close: 4:00PM EDT

89.27 0.00 (0.00%)
After hours: 4:29PM EDT

Stock chart is not supported by your current browser
Previous Close92.71
Open92.20
Bid89.20 x 3200
Ask90.53 x 800
Day's Range89.12 - 92.44
52 Week Range74.13 - 147.17
Volume6,160,794
Avg. Volume6,533,676
Market Cap62.789B
Beta1.35
PE Ratio (TTM)24.82
EPS (TTM)3.60
Earnings DateOct 24, 2018 - Oct 29, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est113.77
Trade prices are not sourced from all markets
  • Final Trade: CELG, BABA & more
    CNBC Videos7 days ago

    Final Trade: CELG, BABA & more

    The "Fast Money" traders share their final trades of the day, including Celgene, Alibaba, Foot Locker and Nordstrom.

  • A Financial Overview of Bausch Health Companies in August
    Market Realist5 hours ago

    A Financial Overview of Bausch Health Companies in August

    In the first half of 2018, Bausch Health reported revenue of $4.1 billion compared to $4.3 billion in the same period last year. Bausch Health reported net income of -$873 million in the second quarter compared to -$38 million in the same period last year. In the first half of 2018, Bausch Health reported net income of -$3.45 billion compared to -$590 million in the same period last year.

  • How Analysts View Bausch Health Companies in August
    Market Realist7 hours ago

    How Analysts View Bausch Health Companies in August

    After the first half of 2018, Bausch raised its full-year adjusted EBITDA guidance from $3.15 billion–$3.30 billion to $3.20 billion–$3.35 billion. In August, Bausch Health’s wholly owned subsidiary Salix Pharmaceuticals and US WorldMeds announced the launch of Lucemyra 0.18 mg tablets in the US market. Right now, Lucemyra is the first and only non-opioid drug indicated for the mitigation of opioid withdrawal symptoms for facilitating rapid opioid discontinuation in adults.

  • 13 of the Cheapest Healthcare Stocks
    Motley Foolyesterday

    13 of the Cheapest Healthcare Stocks

    Each of these stocks has a PEG ratio below 1, but that doesn't make them all worth buying.

  • 3 Top Biotech Stocks to Buy Right Now
    Motley Fool2 days ago

    3 Top Biotech Stocks to Buy Right Now

    Adding these companies to portfolios today could pay off big-time.

  • Turkey Drives Up Worry: Global Week Ahead
    Zacks2 days ago

    Turkey Drives Up Worry: Global Week Ahead

    The Turkish Lira rout that started last week is the big story for this coming week. In turn, U.S. and European earnings seasons are winding down.

  • What Does Alnylam Pharmaceuticals’ Valuation Trend Indicate?
    Market Realist2 days ago

    What Does Alnylam Pharmaceuticals’ Valuation Trend Indicate?

    Alnylam Pharmaceuticals’ (ALNY) investigational RNAi therapeutic drug lumasiran is being developed for the treatment of primary hyperoxaluria type 1 (or PH1). Alnylam expects to initiate a Phase 3 trial of the drug in 2018, with its results expected in late 2019.

  • 3 Top Value Stocks to Buy Right Now
    Motley Fool4 days ago

    3 Top Value Stocks to Buy Right Now

    Maybe not value stocks by the traditional definition, but there's no arguing that CenturyLink, GM, and Celgene are cheap today.

  • Corcept (CORT) Earnings and Revenues Miss Estimates in Q2
    Zacks5 days ago

    Corcept (CORT) Earnings and Revenues Miss Estimates in Q2

    Corcept's (CORT) earnings and revenues lag estimates in Q2. Meanwhile, the company posts positive interim data from phase I/II study on its pipeline candidate relacorilant.

  • Why Celgene Corporation Bounced Back in July
    Motley Fool5 days ago

    Why Celgene Corporation Bounced Back in July

    The biotech company racked up a trio of clinical hits last month, sparking a double-digit rally in its shares.

  • Motley Fool6 days ago

    Carl Icahn Fires Shots at Express Scripts

    Billionaire activist-investor Carl Icahn thinks Cigna’s planned tie-up with Express Scripts is a big blunder.

  • 5 Top Stock Trades for Friday — Buy Yelp, Roku After Earnings Surge?
    InvestorPlace6 days ago

    5 Top Stock Trades for Friday — Buy Yelp, Roku After Earnings Surge?

    What a killer earnings result it was from Roku (NASDAQ:ROKU) and investors are having no reservations about bidding it up in response. Now rallying right into its prior high, keep an eye on Roku. Besting Roku on the day was Yelp (NASDAQ:YELP), which closed higher by nearly 30% vs Wednesday’s close.

  • 7 "Zombie Stocks" That Are Coming Back to Life
    Kiplinger6 days ago

    7 "Zombie Stocks" That Are Coming Back to Life

    Just because a stock has performed badly in the past, doesn't mean it's game over for the future. As investors, we can jump into stocks that are rising. But another strategy is to find poorly performing stocks on the cusp of rebounding. Obviously, this is a more risky approach. What happens if the poor results continue? Well, for instance, you can generate seriously lucrative returns. The key is to cherry-pick your stocks wisely by differentiating between stocks unfairly treated by the market, versus the stocks where all hope is truly lost. Luckily help is at hand. Here, I turned to top analyst ratings to pinpoint stocks that are worth a second look. I used TipRanks to focus on analysts with the sharpest stock picking abilities. These stocks have all posted losses, but the upside potential remains intact. Let's take a closer look at these rebounding stock picks now: SEE ALSO FROM KIPLINGER: 10 of the Market's Most Shorted Stocks

  • Is Crispr Therapeutics Stock Grossly Overvalued?
    Motley Fool6 days ago

    Is Crispr Therapeutics Stock Grossly Overvalued?

    Crispr's stock has started to lose momentum after blasting higher earlier this year. Is the market correcting a prior mistake, or is this dip a buying opportunity?

  • Your first trade for Thursday, August 9
    CNBC6 days ago

    Your first trade for Thursday, August 9

    The "Fast Money" traders share their first moves for the market open.

  • Benzinga6 days ago

    Inspired By Tesla: RBC Speculates On Go-Private Scenario For Celgene

    As Tesla Inc (NASDAQ: TSLA ) explores an exit from the public markets, one Street analyst on Wednesday said Celgene Corporation (NASDAQ: CELG ) could pursue a similar path. The Rating RBC Capital analyst ...

  • Investor's Business Daily7 days ago

    Could Biotech Giant Celgene Join Tesla In The Private Markets?

    Biotech giant Celgene could go private at 120 per share, an analyst suggested Wednesday after similarly sized electric-car maker Tesla confirmed it's discussing the possibility.

  • Musk's Ambitions Rekindle Celgene Privatization Musings at RBC
    Bloomberg7 days ago

    Musk's Ambitions Rekindle Celgene Privatization Musings at RBC

    Elon Musk’s proposal to take Tesla Inc. private re-ignited one sell-side analyst’s thought that biotechnology giant Celgene Corp. may follow suit. RBC Capital Markets analyst Brian Abrahams revisited a concept he floated back in March that a leveraged buyout of the ailing drugmaker would enable it to capture value from its keystone cancer treatment, Revlimid, and take it out from under the microscope that is the public market. “It’s certainly a stretch to say the least,” said Bloomberg Intelligence analyst Asthika Goonewardene, noting he disagrees with the comparison of the two stocks.

  • A Look at Ionis’s Revenue Streams in the Second Quarter
    Market Realist7 days ago

    A Look at Ionis’s Revenue Streams in the Second Quarter

    As discussed earlier, Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to revenues of $112 million during the second quarter of 2017. Ionis missed Wall Street analyst estimates for revenues and EPS in Q2 2018. Ionis reported commercial revenues of $57 million during Q2 2018, over 100% growth as compared to commercial revenues of $24 million during the second quarter of 2017.

  • InvestorPlace7 days ago

    Protagonist Stock Jumps 58% After Re-Review of Test Results

    The mouth-watering 58% rise in shares of Protagonist Therapeutics (NASDAQ:PTGX) on Monday should interest biotech investors. At a market cap of $236.2 million, experienced biotech investors will expect higher than normal volatility. On Monday, Protagonist announced that it secured $22 million in equity financing through the sale of 2.75 million shares.

  • Prothena (PRTA) Q2 Earnings Lag Estimates, Pipeline in Focus
    Zacks7 days ago

    Prothena (PRTA) Q2 Earnings Lag Estimates, Pipeline in Focus

    Prothena (PRTA) posts wider-than-expected loss in the second quarter. With the failure of lead drug, NEOD001, the focus is now mainly on its mid-stage candidate, prasinezumab.

  • See what the IHS Markit Score report has to say about Celgene Corp.
    Markit7 days ago

    See what the IHS Markit Score report has to say about Celgene Corp.

    Celgene Corp NASDAQ/NGS:CELG

  • Bausch Health Companies Stock Rose ~8% after Q2 Results
    Market Realist8 days ago

    Bausch Health Companies Stock Rose ~8% after Q2 Results

    Bausch Health Companies stock was trading at $24.39 today, an ~8.40% increase from yesterday’s close of $22.50. On August 6, Bausch Health stock closed at $22.50, which represents a ~106% increase from its 52-week low of $10.94 on November 2, 2017. After Q2 2018 financial results, Bausch Health Companies raised its full-year adjusted EBITDA guidance from $3.15 billion–$3.30 billion to $3.20 billion–$3.35 billion. Bausch Health anticipates net revenues for the fiscal year 2018 to be in the range of $8.15 billion and $8.35 billion. 

  • Estimates and Recommendations for BeiGene on August 7
    Market Realist8 days ago

    Estimates and Recommendations for BeiGene on August 7

    BeiGene (BGNE) reported revenues of $32.5 million and EPS of -$2.03 in the first quarter. Analysts expect BeiGene to report EPS of -$2.06 on revenues of $22.5 million during the second quarter. This represents 100.0% growth in its YoY (year-over-year) revenues, compared to zero revenues during the second quarter of 2017. The chart below compares analysts’ recommendations over the last 12 months.

  • Expectations from BeiGene’s Q2 2018 Earnings
    Market Realist8 days ago

    Expectations from BeiGene’s Q2 2018 Earnings

    BeiGene (BGNE) is a clinical-stage biopharmaceutical company that develops molecularly targeted and immuno-oncology drugs for cancer. BeiGene also markets the drugs Abraxane, Revlimid, and Vidaza in China under its licensing agreement with Celgene (CELG).